Welcome to our dedicated page for Deciphera Pharmaceuticals news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals stock.
Deciphera Pharmaceuticals, Inc. (symbol: DCPH) is a biotechnology company founded in 2003 with a deep scientific understanding of kinase inhibitors. Based in Boston, with research capabilities near the University of Kansas, Deciphera specializes in developing advanced kinase-inhibiting drugs for cancer and immunological diseases. The company has identified small molecule leads for over 50 kinase targets and has built a robust pipeline of drug candidates, including three clinical-stage and two research-stage programs.
The company's lead drug candidate, DCC-2618, is designed to inhibit mutant or amplified KIT and Pdgfra kinases, which drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, Deciphera is developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib, which are focused on treating different types of cancers.
Geographically, Deciphera's operations are concentrated in the United States. The company has recently achieved significant milestones, including the successful completion of a tender offer by Ono Pharmaceutical Co., Ltd. to acquire all outstanding shares of Deciphera for approximately $2.4 billion. Following this acquisition, Deciphera became a wholly owned subsidiary of Ono, who will leverage its research and development capabilities in oncology and its sales power in Europe and the United States to expand its global presence.
The merger with Ono Pharmaceutical marks a new phase for Deciphera, where the combined expertise and resources are expected to accelerate the growth of their pipeline and contribute significantly to the global fight against cancer and other diseases.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that it will release its first quarter 2023 financial results on May 3, 2023, at 8:00 AM ET. A live conference call will follow to discuss the results and provide a corporate update. Interested parties can access the call through a designated link or via the company’s website. Deciphera focuses on developing innovative medicines for cancer patients, leveraging its proprietary switch-control kinase inhibitor platform. The company’s product, QINLOCK®, is a switch-control inhibitor approved for fourth-line treatment of GIST in several regions, including the U.S. and European Union. For more details, visit deciphera.com.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that its management will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on April 26, 2023, at 10:30 AM ET. The event aims to discuss the company's progress in developing innovative medicines for cancer treatment.
A live webcast will be accessible on the Company’s website under the “Investors” section, with an archived replay available for 90 days post-event. Deciphera's focus is on commercializing new treatments, notably QINLOCK®, a switch-control kinase inhibitor approved in multiple countries including the US, Canada, and the EU for the treatment of fourth-line GIST.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that QINLOCK is now included in the NCCN Guidelines as a preferred regimen for second-line gastrointestinal stromal tumor (GIST) patients intolerant to sunitinib. The FDA granted Breakthrough Therapy Designation for QINLOCK, indicating its potential to improve treatment outcomes for adult patients with unresectable or metastatic GIST with specific mutations. The company plans to initiate the INSIGHT Phase 3 Study in late 2023, aimed at evaluating QINLOCK against sunitinib in similar patient populations. This follows positive results from the INTRIGUE study, demonstrating QINLOCK's efficacy and tolerability profile.
FAQ
What is the current stock price of Deciphera Pharmaceuticals (DCPH)?
What is the market cap of Deciphera Pharmaceuticals (DCPH)?
What does Deciphera Pharmaceuticals, Inc. specialize in?
Where is Deciphera Pharmaceuticals based?
What are the key drug candidates in Deciphera's pipeline?
What is DCC-2618 designed to treat?
Who acquired Deciphera Pharmaceuticals and for how much?
What will be the impact of the acquisition by Ono Pharmaceutical on Deciphera Pharmaceuticals?
What is the significance of Deciphera becoming a wholly owned subsidiary of Ono?
What are the research capabilities of Deciphera Pharmaceuticals?
Are Deciphera's operations limited to the United States?
What recent achievements has Deciphera Pharmaceuticals accomplished?
